All News

Large-scale genome-wide association study of R A (276,020 samples in 5 ancestral grps) identified 124 loci (P < 5 × 10−8), 34 being novel. Candidate genes showed essential roles for TNIP2, TNFRSF11A, WISP1 in RA. https://t.co/jk1ePlen5l https://t.co/aSIZYJ9oky

Links:

Dr. John Cush RheumNow ( View Tweet)
Without DMARDS, Shoulder Arthroplasty Increasing in Rheumatoid Arthritis The need for total shoulder arthroplasty (TSA) in rheumatoid arthritis (RA) patients appears to depend on the use of DMARDs, according to Seminars in Arthroplasty. https://t.co/iGAQaa7Ppc https://t.co/AbteC427wI

Links:

Dr. John Cush RheumNow ( View Tweet)
Pregnancy & RA: metanalysis of 9 studies, 12K RA pts met vs 10 million controls. RA preg have more maternal complications (C sect OR 1.55; preeclampsia OR, 1.6; preterm OR, 1.8) & neonatal probs (low gestat wt, ICU OR 1.34, & stillbirths OR, 1.99). https://t.co/1hA0zGsDtk https://t.co/awaV07GbEv

Links:

Dr. John Cush RheumNow ( View Tweet)
TSR Shoulder replacement

Without DMARDS, Shoulder Arthroplasty Increasing in Rheumatoid Arthritis

d Jack Cush, MD

The need for total shoulder arthroplasty (TSA) in rheumatoid arthritis (RA) patients appears to depend on the use of disease modifying antirheumatic drugs (DMARDs), according to Seminars in Arthroplasty.

Read Article
Skin,cancer,squamous,cell

Does Methotrexate Increase Skin Cancer Risk?

d Jack Cush, MD

There are several reports suggesting a link between methotrexate (MTX) use and certain skin cancers, yet these are confounded by a higher risk of skin cancers with inflammatory conditions like rheumatoid arthritis of which MTX is the most common treatment.

Read Article
Treatment failures studied in 718 RA pts - csDMARDs D/Cs intolerance (22%), inefficacy (20%), acute Rxns (5%), severe infx(0.6%) - bDMARDs D/Cs inefficacy (29%), intolerance (10%), acute Rxns (6%), severe infx (1.5%) - Multi-drug ifailure 5.7-8.4% https://t.co/FdoP77uELe https://t.co/dQjTNncABc

Links:

Dr. John Cush RheumNow ( View Tweet)
antibody (Keep)

New 5 Peptide Autoantibody Panel Complements RA Diagnosis

d MedPage Today

Antibodies to peptides not currently used for rheumatoid arthritis (RA) diagnosis helped identify patients with untreated early disease that conventional biomarkers missed, researchers said.

Read Article
New Guideline: Vaccinations OK With Few Tweaks for Rheum Patients Nearly all available vaccines can be given to people with rheumatologic diseases, according to a new, detailed guideline from the ACR. https://t.co/514mIylgzj https://t.co/9Zq9pGcujV

Links:

Dr. John Cush RheumNow ( View Tweet)
Herpes Zoster with JAK Inhibitors A recent review a higher HZ risk with JAKi therapy shows the HZ-risk in RA and UC to be higher than PsA when treated with usual doses of TOFA, especially those given higher TOFA doses or concomitant glucocorticoids. https://t.co/rlYXJWONyS https://t.co/nwqbbp6Ci3

Links:

Dr. John Cush RheumNow ( View Tweet)
Is JAKi therapy safe in RA-ILD pts? Italian retrospective study (2018-June 2022) w/ 43 RA pts & HRCT proven ILD (med age 69yrs) & Rx w/ JAKi. After 19 mos F/U, the FVC was stable in 79%, improved in 11%, & worse in 11%. DLCO & HRCT trend was similar. https://t.co/T0rP96FM0Z https://t.co/W8NFtfevQg

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA has approved the 1st BTK (Bruton’s tyrosine kinase) inhibitor (Jaypirca™ or pirtobrutinib) for adults with refractory mantle cell lymphoma. BTK inhibitors are also being developed for use in MS, RA, SLE, pemphigus & more https://t.co/599tK21H1Z https://t.co/KSqMMDWmfd

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast square

Burnout #10 (2.3.2023)

d Jack Cush, MD

Dr. Jack Cush reviews the past week of news on RheumNow.com.

Read Article
Feb 3rd, today is #NationalWomenPhysiciansDay. The date honors Dr. Elizabeth Blackwell, 1st woman to receive an MD United States (1849). RheumNow will devote the whole month of April 2023 to our Campaign on Women in Rheumatology - stay tuned! https://t.co/l1M56L8h9N https://t.co/eQpetW02CE

Links:

Dr. John Cush RheumNow ( View Tweet)
PNAS has a novel approach to #RA Tx; bioengineered probiotic(Lactobacillus reuteri) orally delivers a peptide Kv1.3 channel blocker to RxRA. Kv1.3 is expressed on CCR7− effector memory T cells. Blocking Kv1.3 improves RA & PSO in rat models. https://t.co/DyyXi2GUH2 https://t.co/8nDyFv9DWx

Links:

Dr. John Cush RheumNow ( View Tweet)
Swiss RA registry assessed outcomes after 1st JAKi. 400 RA pts starting/failing JAKi were switched to 2nd JAKi or TNFi or other MOA biologic. ~40% had prior bDMARDs. Retention was higher w/ 2nd JAK (918d)i vs other options. TNFi (335d) or OMA (918d). https://t.co/3A3KwVcTCN https://t.co/UFLPGfmzNv

Links:

Dr. John Cush RheumNow ( View Tweet)
Rheumpix

Coffee with milk may have an anti-inflammatory effect

d EurekAlert!

Can something as simple as a cup of coffee with milk have an anti-inflammatory effect in humans? Apparently so, according to a new study from the University of Copenhagen. A combination of proteins and antioxidants doubles the anti-inflammatory properties.

Read Article
Rheumatic Disease - IBD Overlap Nearly one in 10 patients with IBD also have rheumatologic disorders, meaning that specialists have to talk to each other to develop a treatment plan that works for both conditions, a researcher suggested. https://t.co/s3u9q8Sw9Y https://t.co/RjFyEcm6FA

Links:

Dr. John Cush RheumNow ( View Tweet)
JAK-pot Study: To Cycle or Switch after JAK inhibitor Failure? Data from 17 international registries suggest that for RA patients failing their first JAKi, it did not matter if they were cycled to another JAKi or switched to a bDMARD. https://t.co/WunRxeF5Wm https://t.co/cOIjglnPNU

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast square

Simon Says “Don’t Do This” (1.27.2022)

d Jack Cush, MD

Dr. Jack Cush reviews this week’s journal articles, focuses on studies that should not have been done and responds to viewer questions in Ask Cush Anything.

Read Article
Early Ph IIa study of ATI-450 (Zunsemetinib), an investigational selective MAP kinase–2 (MK2) blocker leds to a sustained antiinflammatory effect; studied in 19 RA pts w/ ACR 20/50/70 of 60%/33%/20% at wk 12. https://t.co/IyjJCgdXG2

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.